Laurus Labs FY2026 Revenue Reaches ₹6,813 Crore

FY2026 revenue update

Laurus Labs generated revenue of ₹6,813 crore in FY2026, according to the company information provided with its investor presentation announcement. The pharmaceutical and biotechnology company will discuss its standalone and consolidated financial results for the quarter and year ended March 31, 2026, with investors and analysts. The scheduled call is an important disclosure event because it covers both the March quarter and the full financial year. Laurus Labs is listed on the BSE and the NSE, where it trades under the codes 540222 and LAURUSLABS, respectively. The company said the related presentation would also be uploaded to its website.

Investor call scheduled for April 30

The investors and analysts call was scheduled for April 30, 2026, at 5:00 p.m. IST. Laurus Labs had previously intimated the market about the call on April 9, 2026. The company stated that the presentation relates to its financial results for the period ended March 31, 2026. The announcement does not provide a detailed quarterly revenue, profit, margin, segment, or guidance figure. Investors would therefore need to rely on the presentation and the accompanying financial disclosures for those details.

Revenue rises from FY2025 level

FY2026 revenue of ₹6,813 crore was higher than the ₹5,554 crore reported for FY2025. This represents an increase of ₹1,259 crore, or about 22.7%, based on the two annual revenue figures. The comparison shows a marked increase in the company’s reported annual revenue base over one year. Laurus Labs had reported ₹5,041 crore in FY2024, before the FY2025 revenue increase. The company’s FY2026 figure is also above the ₹4,800 crore-plus revenue level cited for FY2021.

Revenue trend at a glance

The figures show that annual revenue increased in each of the three reported financial years. From FY2024 to FY2026, revenue increased by ₹1,772 crore. The provided disclosures do not break this FY2026 increase into business divisions. They also do not specify the contribution from APIs, finished dosage forms, CDMO operations, or specialty ingredients for the full year.

Company’s operating profile

Laurus Labs describes itself as a research-driven pharmaceutical and biotechnology company. It has a leadership position in select active pharmaceutical ingredients, or APIs, and finished dosage forms, or FDFs. Its therapeutic focus includes anti-retroviral, oncology, cardiovascular, and gastro products. The company also offers contract development and manufacturing organisation, or CDMO, services for innovators from early development through commercial production. According to its September 2025 presentation, Laurus employed more than 7,042 people, including more than 2,632 scientists.

Manufacturing and regulatory footprint

The company has stated that it operates 15 facilities approved by global regulators, including the USFDA, WHO and EMA. This manufacturing and regulatory footprint is relevant to its ability to serve pharmaceutical customers across markets. Laurus operates across APIs and intermediates, finished dosage forms, CDMO services, and specialty ingredients for the nutraceutical and allied industry. These businesses give the company exposure to both product manufacturing and development-led contract work. The available FY2026 announcement does not provide any new facility, regulatory inspection, or capacity-expansion update.

Earlier quarterly performance context

Laurus had reported ₹1,415 crore of consolidated revenue in the December 2024 quarter, up 18% year on year, according to its Q3 FY2025 presentation. For the first nine months of FY2025, it reported revenue of ₹3,834 crore, representing 6% growth. The company had attributed the quarterly revenue growth to stronger deliveries in its CDMO and FDF divisions, partly offset by a decline in API sales. In the June 2026 quarter, Laurus later reported revenue of ₹2,026 crore, with 29% growth, and EBITDA of ₹644 crore with a 31.8% margin. Those figures relate to Q1 FY2027 and are separate from the FY2026 results event.

What investors will track

The FY2026 revenue figure establishes the scale of the company’s annual business, while the scheduled results discussion provides the forum for further financial detail. Investors will likely review the disclosed standalone and consolidated numbers for the March quarter and full year. Segment-level performance, profitability, operating margins, project deliveries and business commentary would be relevant where included in the company’s formal presentation. However, the announcement itself does not provide these FY2026 details. It is important to distinguish the confirmed revenue figure from metrics that have not been disclosed in the supplied material.

Market relevance of the disclosure

For a listed pharmaceutical manufacturer, annual revenue trends are closely watched alongside profitability, product mix and regulatory execution. Laurus Labs’ reported FY2026 revenue was ₹1,259 crore above its FY2025 revenue. Its business spans generic APIs, finished dosage forms and CDMO services, each of which can influence the company’s reported financial mix. The full-year results presentation is therefore relevant for shareholders seeking management’s explanation of the reported performance. No share-price movement, dividend decision, earnings-per-share figure, or FY2026 margin figure is included in the information provided.

Conclusion

Laurus Labs reported FY2026 revenue of ₹6,813 crore, compared with ₹5,554 crore in FY2025. The company scheduled its investors and analysts call for April 30, 2026, at 5:00 p.m. IST to discuss results for the quarter and year ended March 31, 2026. The presentation was to be made available on the company’s website. Further details on the full-year financial performance would depend on the formal results and investor presentation disclosures.